Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT

Exclusion Criteria

• •1. Left ventricular ejection fraction measured by echocardiogram \> 45% or diagnosed with heart failure with preserved ejection fraction.
• •2. Age ≤ 18 years old.
• •3. Allergic to anti-heart failure medications including ACEI/ARB/ARNI, beta blockers, SGLT2i, oral diuretics and vericiguat.
• •4. Diagnosed as other diseases with symptoms similar to heart failure such as acute exacerbation of chronic obstructive pulmonary disease, etc.
• •5. Dignosed with acute coronary syndrome, including unstable angina, non ST-elevation myocardial infarction and ST-elevation myocardial infarction. Received percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 3 months prior to the trial start, or indication for PCI or CABG at the trial start.
• •6. Hepatic insufficiency classified as Child-Pugh B or C.
• •7. Diagnosed with restrictive cardiomyopathy.
• •8. Diagnosed with cardiac amyloidosis, Fabry disease or other rare cardiomyopathy.
• •9. Diagnosed with systematic lupus erythematosus or other autoimmune disease.
• •10. Diagnosed with or suspect diagnosed with active tumor.
• •11. Diagnosed with idiopathic pulmonary hypertension, receiving PDE-5 inhibitor or other sGC stimulators.
• •12. Pregnant woman.
• •13. Combined with severe infection at admission or combined with uncontrolled tuberculosis.
• •14. Diagnosed with severe and uncontrolled congenital heart disease.
• •15. Patients with rheumatic valvular disease who have indications for surgery but have not undergone surgical treatment.